Gut · 2026
Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study.
СтатьяСравнительное исследованиеВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sperber Ami D, Hreinsson Johann P, Simrén Magnus, Drossman Douglas A, Andresen Viola, Bor Serhat, Dumitrascu Dan L, Fang Xiucai, Fei Guijun, Fernandez Luis Bustos, Francesconi Carlos, Fukudo Shin, Lee Sang Kil, Melchior Chloé, Mulak Agata, Peery Anne F, Rodrigues David M, Santos Javier, Schmulson Max, Vasant Dipesh H, Tack Jan, Taft Tiffany, Palsson Olafur S
Аннотация
BACKGROUND: The recently published Rome V adult diagnostic criteria facilitated an updated epidemiological survey of disorders of gut-brain interaction (DGBI).
OBJECTIVE: We aimed to describe the global epidemiology of DGBI using the Rome V criteria and compare it with the Rome IV Rome Foundation Global Epidemiology Study.
METHODS: A population-based Internet survey of 28,771 adults was conducted in 15 countries using the Rome V diagnostic questionnaire. DGBI prevalence was determined and compared with the Rome IV data. Multivariable logistic regression models were used to examine associations of demographic factors to Rome V DGBI status in the global population and to assess potentially associated clinical factors.
RESULTS: The surveys yielded similar results. The prevalence of at least one DGBI using the Rome V criteria was 40.9%, compared with 40.5% for Rome IV. In both, the prevalence was higher among females and decreased with increasing age. In the Rome V sample (25 DGBI), the most prevalent oesophageal disorder was functional dysphagia at 4.1%, the most prevalent gastroduodenal disorder was functional dyspepsia at 8.1%, unclassified bowel disorder was the most prevalent bowel disorder (9.6%), followed by chronic constipation (8.9%) and IBS (8.5%) and proctalgia fugax was the most prevalent anorectal disorder (7.3%). The prevalence rates for two new DGBI were 5.1% for abdominal migraine and 1.4% for inability to belch syndrome.
CONCLUSION: The Rome V global prevalence of DGBI is consistent with Rome IV. This bolsters confidence in the validity of prevalence rates for DGBI and reaffirms their high global burden.
OBJECTIVE: We aimed to describe the global epidemiology of DGBI using the Rome V criteria and compare it with the Rome IV Rome Foundation Global Epidemiology Study.
METHODS: A population-based Internet survey of 28,771 adults was conducted in 15 countries using the Rome V diagnostic questionnaire. DGBI prevalence was determined and compared with the Rome IV data. Multivariable logistic regression models were used to examine associations of demographic factors to Rome V DGBI status in the global population and to assess potentially associated clinical factors.
RESULTS: The surveys yielded similar results. The prevalence of at least one DGBI using the Rome V criteria was 40.9%, compared with 40.5% for Rome IV. In both, the prevalence was higher among females and decreased with increasing age. In the Rome V sample (25 DGBI), the most prevalent oesophageal disorder was functional dysphagia at 4.1%, the most prevalent gastroduodenal disorder was functional dyspepsia at 8.1%, unclassified bowel disorder was the most prevalent bowel disorder (9.6%), followed by chronic constipation (8.9%) and IBS (8.5%) and proctalgia fugax was the most prevalent anorectal disorder (7.3%). The prevalence rates for two new DGBI were 5.1% for abdominal migraine and 1.4% for inability to belch syndrome.
CONCLUSION: The Rome V global prevalence of DGBI is consistent with Rome IV. This bolsters confidence in the validity of prevalence rates for DGBI and reaffirms their high global burden.